# Efficacy and Safety of SHR-3167 and Insulin Glargine in Type 2 Diabetes Subjects

> **NCT06688123** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 275 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** SHR-3167
- **DRUG:** SHR-3167
- **DRUG:** Insulin glargine

## Key facts

- **NCT ID:** NCT06688123
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-01-08
- **Primary completion:** 2026-03-30
- **Final completion:** 2026-04-30
- **Target enrollment:** 275 (ACTUAL)
- **Last updated:** 2025-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06688123

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06688123, "Efficacy and Safety of SHR-3167 and Insulin Glargine in Type 2 Diabetes Subjects". Retrieved via AI Analytics 2026-09-27 from https://api.ai-analytics.org/clinical/NCT06688123. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*